MS432

MS432 is a first-in-class and highly selective PD0325901-based von Hippel-Lindau -recruiting PROTAC degrader for MEK1 and MEK2 . MS432 displays good plasma exposure in mice, exhibiting DC 50 values of 31 nM and 17 nM for MEK1 , MEK2 in HT29 cells respectively In Vitro MS432 (compound 23) is potent in reducing MEK1/2 protein levels in COLO 205 cells (DC 50 (MEK1) = 18 ± 7 nM, DC 50 (MEK2) = 11 ± 2 nM) and UACC257 cells (DC 50 (MEK1) = 56 ± 25 nM, DC 50 (MEK2) = 27 ± 19 nM). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: (HT-29, SK-MEL-28, COLO 205 and UACC 257 cell lines. Concentration: 0-1 μM. Incubation Time: 72 hours. Result: Effectively inhibited proliferation of these CRC and melanoma cells in a concentration-dependent manner, with GI 50 values ranging from 30 to 200 nM. In Vivo MS432 (compound 23) displays good plasma exposure, which is approximately 3 to 20-fold higher than the GI 50 values of compound 23 in the tested cancer cell lines . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Swiss Albino mice . Dosage: 50 mg/kg (Pharmacokinetic Analysis). Administration: IP Result: Displays good plasma exposure with the maximum plasma concentration of 1,400 nM detected at 0.5 hour post dosing and plasma concentration of 710 nM at 8 hours post dosing. Form:Solid IC50& Target:MEK1 31 nM (DC 50 , in HT29 cells) MEK2 17 nM (DC 50 , in HT29 cells) MEK1 31 nM (DC 50 , in SK-MEL-28 cells) MEK2 9.3 nM (DC 50 , in SK-MEL-28 cells)

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet